AnaptysBio, Inc

(NASDAQ:ANAB)

Latest On AnaptysBio, Inc (ANAB):

Date/Time Type Description Signal Details
2023-05-22 18:46 ESTNewsAnaptysBio upgraded to neutral at JP Morgan on clinical executionN/A
2023-05-21 00:00 ESTNewsStocks To Watch: Debt Ceiling Drama, Nvidia Earnings And Healthcare ConferencesN/A
2023-05-18 17:01 ESTNewsAnaptysBio initiated Outperform at TD Cowen on anti-inflammatory agentsN/A
2023-05-12 06:14 ESTNewsAnaptysBio GAAP EPS of -$1.58 misses by $0.53, revenue of $1.4M misses by $1.48MN/A
2023-04-25 14:45 ESTNewsGSK's Jemperli gets review in EU for expanded use in uterus cancerN/A
2023-03-31 01:05 ESTNewsAnaptysBio: Upside Could Be Lying Ahead Very NicelyN/A
2023-03-01 22:46 ESTNewsAnaptysBio GAAP EPS of -$0.93, revenue of $6.8MN/A
2023-01-13 19:42 ESTNewsAnaptysBio rises 10% on stock repurchase of up to $50MN/A
2022-11-09 02:12 ESTNewsAnaptysBio GAAP EPS of -$1.18 misses by $0.56, revenue of $1.29M misses by $12.14MN/A
2022-11-01 22:23 ESTNewsAnaptysBio raised to Buy at Guggenheim on prospects for checkpoint agonistsN/A
2022-10-05 18:17 ESTNewsAnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trialN/A
2022-09-14 00:51 ESTNewsAnaptysBio cut to Hold at Truist citing high bar for hair loss treatmentN/A
2022-09-12 13:42 ESTNewsAnaptysBio sells royalties from GSK-partnered Zejula for $45MN/A
2022-09-01 01:51 ESTNewsAnaptysBio skin condition candidate fails mid-stage trial; shares down 16%N/A
2022-08-08 18:55 ESTNewsAnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4MN/A
2022-05-04 22:42 ESTNewsAnaptysBio GAAP EPS of -$1.31 misses by $0.32, revenue of $0.97M misses by $4.08MN/A
2022-03-22 16:43 ESTNewsAnaptysBio names interim CEO as Hamza Suria steps downN/A
2022-03-22 16:42 ESTNewsAnaptysBio cut to neutral at Guggenheim on future of pipelineN/A
2022-03-14 23:38 ESTNewsAnaptysBio acne treatment imsidolimab fails in mid-stage trial; shares down 12%N/A
2021-11-05 01:02 ESTNewsAnaptysBio EPS beats by $0.64, beats on revenueN/A
2021-10-26 12:05 ESTNewsAnaptysBio climbs 14%, will monetize portion of JEMPERLI royalties for $250M with SagardN/A
2021-10-04 23:16 ESTNewsAnaptysBio reports updated data from imsidolimab mid-stage study in pustular psoriasisN/A
2021-08-18 04:46 ESTNewsAnaptysBio secures $20M milestone payment from GSK after JEMPERLI FDA approvalN/A
2021-08-18 04:46 ESTNewsANAB, TLRY, PFMT and BMRN among after hours moversN/A
2021-08-09 22:59 ESTNewsAnaptysBio EPS beats by $0.12, beats on revenueN/A
2021-07-20 18:44 ESTNewsAnaptysBio gains after report the company received a takeover offerN/A
2021-05-05 11:31 ESTNewsAnaptysBio EPS beats by $0.03, beats on revenueN/A
2021-04-24 05:15 ESTNewsAnaptysBio trades higher after FDA approval for Jemperli triggers $20M milestone paymentN/A
2021-04-24 05:14 ESTNewsGlaxoSmithKline wins EU approval for Jemperli in endometrial cancerN/A
2021-04-23 07:49 ESTNewsAnaptysBio is trading higher after FDA approval for Jemperli in endometrial cancer (updated)N/A
2021-03-17 12:05 ESTAnalyst RatingThe Analyst Target Price has increased from $26.75 to $28.5.Buy
2021-03-16 19:18 ESTNewsAnaptysBio is set for a catalyst-rich phase after the recent selloff: TruistN/A
2021-03-10 15:05 ESTAnalyst RatingThe Analyst Target Price has decreased from $30.75 to $26.75.Neutral
2021-03-09 03:06 ESTAnalyst RatingThe Analyst Target Price has decreased from $33.25 to $30.75.Neutral
2021-03-08 17:28 ESTNewsAnaptysBio fails in mid-stage study for Imsidolimab in skin diseaseN/A
2021-03-08 17:27 ESTNewsAnaptysBio gets double downgrade at JPM after Imsidolimab trial failureN/A
2021-03-03 02:39 ESTNewsAnaptysBio: Upcoming Catalyst Seems Like Quite The GambleN/A
2021-03-01 15:05 ESTAnalyst RatingThe Analyst Target Price has increased from $29.8 to $33.25.Buy
2021-03-01 15:05 ESTEarnings EstimateAn EPS average of -$2.43 is estimated for the 2022 year.Sell
2021-03-01 15:05 ESTEarnings EstimateAn EPS average of -$0.69 is estimated for the quarter ending on June 30, 2021.Sell
2021-02-26 15:05 ESTFinancialsCompany financials have been released.Neutral
2021-02-25 19:20 ESTNewsAnaptysBio EPS beats by $0.15, beats on revenueN/A
2021-02-12 11:05 ESTAnalyst RatingThe Analyst Target Price has increased from $28 to $29.8.Neutral
2021-02-11 20:59 ESTNewsAnaptysBio rises after double-upgrade from JPM; positive risk/reward profile citedN/A
2021-02-11 20:58 ESTNewsAnaptysBio: Troubled History Of Drug DevelopmentN/A
2020-12-13 03:11 ESTFinancialsCompany financials have been released.Neutral
2020-12-01 10:36 ESTNewsAnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% UpsideN/A
2020-11-18 06:57 ESTNewsAnaptysBio (ANAB) Investor Presentation - SlideshowN/A
2020-11-15 11:10 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 11:07 ESTAnalyst RatingThe Analyst Target Price has increased from $27.5 to $28.Neutral

About AnaptysBio, Inc (ANAB):

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

See Advanced Chart

General

  • Name AnaptysBio, Inc
  • Symbol ANAB
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 94
  • Fiscal Year EndDecember
  • IPO Date2017-01-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.anaptysbio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 8.07
  • Price/Book (Most Recent Quarter) 1.53
  • Enterprise Value Revenue 2.85
  • Enterprise Value EBITDA 0.11
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.01
  • Next Year EPS Estimate -$3.09
  • Next Quarter EPS Estimate -$0.61
  • Profit Margin -27%
  • Operating Margin -32%
  • Return on Assets -4%
  • Return on Equity -5%
  • Revenue 75 million
  • Earnings Per Share -$3.01
  • Revenue Per Share $2.75
  • Gross Profit -5025000
  • Quarterly Earnings Growth 1900%
View More

Highlights

  • Market Capitalization 587.28 million
  • EBITDA -87543000
  • PE Ratio -6.14
  • Analyst Target Price $28.5
  • Book Value Per Share $14.50
View More

Share Statistics

  • Shares Outstanding 27.37 million
  • Shares Float 15.89 million
  • % Held by Insiders 77%
  • % Held by Institutions 106.22%
  • Shares Short 3.81 million
  • Shares Short Prior Month 3.74 million
  • Short Ratio 8.99
  • Short % of Float 21%
  • Short % of Shares Outstanding 14%
View More

Technicals

  • Beta 0.13
  • 52 Week High $35.86
  • 52 Week Low $12.46
  • 50 Day Moving Average 26.72
  • 200 Day Moving Average 23.55
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

AnaptysBio, Inc (ANAB) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

AnaptysBio, Inc (ANAB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$60 million$1.20$0.6098.87%
2020-09-302020-11-04$N/A-$0.87-$0.69-26.45%
2020-06-302020-08-10$N/A-$0.79-$0.65-21.18%
2020-03-312020-05-06$N/A-$0.30-$0.8062.5%
2019-12-312020-03-02$3 million-$0.75-$1.2841.36%
2019-09-302019-11-08$N/A-$1.15-$1.14-0.46%
2019-06-302019-08-08$5 million-$0.89-$0.956.66%
2019-03-312019-05-07$N/A-$0.82-$0.78-4.75%
2018-12-312019-02-28$N/A-$0.64-$0.8625.93%
2018-09-302018-11-08$5 million-$0.66-$0.706.16%
2018-06-302018-08-07$N/A-$0.57-$0.6714.41%
2018-03-312018-05-08$N/A-$0.63-$0.46-36.22%
2017-12-312018-03-05$3 million-$0.30-$0.4228.37%
2017-09-302017-11-07$-7000000-$0.45-$0.474.56%
2017-06-302017-08-10$7 million-$0.13-$0.4269.34%
2017-03-312017-05-11$N/A-$0.75-$0.18-310.96%
2016-12-312017-03-08$2.75 million-$0.19-$0.10-86.34%

AnaptysBio, Inc (ANAB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

AnaptysBio, Inc (ANAB) Chart:

AnaptysBio, Inc (ANAB) News:

Below you will find a list of latest news for AnaptysBio, Inc (ANAB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

AnaptysBio, Inc (ANAB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-07-18100CALL0 0862.74TRUE00
2025-07-1812.50CALL0 0695.29TRUE00
2025-07-18150CALL0 0564.9TRUE00
2025-07-1817.55.4CALL0 7159.67TRUE00
2025-07-18203CALL0 26212.94TRUE00
2025-07-1822.52.8CALL4 1004148.63TRUE00
2025-07-18251.6CALL1 1562.37TRUE1.60
2025-07-18300.5CALL0 341120.71FALSE00
2025-07-18350CALL0 0182.53FALSE00
2025-07-18100PUT0 0487.3FALSE00
2025-07-1812.50.55PUT0 20702.38FALSE00
2025-07-18150.05PUT0 0189.57FALSE00
2025-07-1817.50.05PUT0 1016127.8FALSE00
2025-07-18200.1PUT0 108367.6FALSE00
2025-07-1822.51PUT0 90197.66FALSE00
2025-07-18252.7PUT0 1131.6FALSE00
2025-07-18300PUT0 0133.83TRUE00
2025-07-18350PUT0 0176.42TRUE00
2025-08-152.50CALL0 00TRUE00
2025-08-1550CALL0 0710.26TRUE00
2025-08-157.50CALL0 0517.26TRUE00
2025-08-151013CALL0 109397.14TRUE00
2025-08-1512.50CALL0 1214.63TRUE00
2025-08-15159.41CALL0 24170.59TRUE00
2025-08-1517.55.8CALL0 221133.3TRUE00
2025-08-15206.5CALL0 60119.69TRUE00
2025-08-1522.54.21CALL1 1359.32TRUE4.210
2025-08-15252.75CALL5 15765.8TRUE0.120.05
2025-08-15300.5CALL0 6468.05FALSE00
2025-08-15350.4CALL0 9121.64FALSE00
2025-08-152.50PUT0 0565.97FALSE00
2025-08-1550PUT0 0720.55FALSE00
2025-08-157.50PUT0 5524.77FALSE00
2025-08-15100.4PUT0 25411.74FALSE00
2025-08-1512.50PUT0 7332.14FALSE00
2025-08-15151.1PUT0 21181.29FALSE00
2025-08-1517.52.35PUT0 17218.94FALSE00
2025-08-15200PUT0 1891.02FALSE00
2025-08-1522.51.8PUT0 1783.46FALSE00
2025-08-15254.5PUT0 1358.24FALSE00
2025-08-15300PUT0 180TRUE00
2025-08-15350PUT0 0109.99TRUE00
2025-11-212.50CALL0 0826.37TRUE00
2025-11-2150CALL0 0366.26TRUE00
2025-11-217.50CALL0 0169.59TRUE00
2025-11-21100CALL0 0145.52TRUE00
2025-11-2112.50CALL0 1119.36TRUE00
2025-11-21150CALL0 099.7TRUE00
2025-11-2117.50CALL0 19890.69TRUE00
2025-11-21207.53CALL0 6682.44TRUE00
2025-11-2122.50CALL0 1678.11TRUE00
2025-11-21254.61CALL0 1272.65TRUE00
2025-11-21303CALL2 23767.63FALSE30
2025-11-21350CALL0 162.18FALSE00
2025-11-212.50PUT0 0960.88FALSE00
2025-11-2150PUT0 0376.48FALSE00
2025-11-217.50PUT0 0274.28FALSE00
2025-11-21100PUT0 0215.43FALSE00
2025-11-2112.50PUT0 5130.96FALSE00
2025-11-21150.85PUT0 495.35FALSE00
2025-11-2117.50PUT0 0114.06FALSE00
2025-11-21200PUT0 279.09FALSE00
2025-11-2122.53.8PUT0 275.41FALSE00
2025-11-21250PUT0 078.74FALSE00
2025-11-21300PUT0 060.46TRUE00
2025-11-21350PUT0 075.19TRUE00
2026-01-1612.50CALL0 094.4TRUE00
2026-01-16150CALL0 094.42TRUE00
2026-01-1617.56CALL0 183.49TRUE00
2026-01-16207.9CALL0 578.9TRUE00
2026-01-1622.50CALL0 069.17TRUE00
2026-01-16255.66CALL6 1166.56TRUE-0.69-0.11
2026-01-16304CALL0 376.7FALSE00
2026-01-16352.66CALL0 369.74FALSE00
2026-01-1612.50PUT0 0146.99FALSE00
2026-01-16150PUT0 094.76FALSE00
2026-01-1617.51.9PUT0 374.27FALSE00
2026-01-16204PUT0 566.2FALSE00
2026-01-1622.50PUT0 054.98FALSE00
2026-01-16250PUT0 065.68FALSE00
2026-01-16300PUT0 066.19TRUE00
2026-01-163512.8PUT0 1073.35TRUE00
2026-02-2012.50CALL0 0101.81TRUE00
2026-02-20150CALL0 084.46TRUE00
2026-02-2017.50CALL0 082.81TRUE00
2026-02-20200CALL0 077.56TRUE00
2026-02-2022.50CALL0 073.8TRUE00
2026-02-20254.44CALL0 271.66TRUE00
2026-02-20300CALL0 065.42FALSE00
2026-02-20352CALL0 167.5FALSE00
2026-02-2012.50PUT0 095.05FALSE00
2026-02-20150PUT0 075.88FALSE00
2026-02-2017.50PUT0 068.12FALSE00
2026-02-20200PUT0 073.59FALSE00
2026-02-2022.50PUT0 070.74FALSE00
2026-02-20250PUT0 063.57FALSE00
2026-02-20300PUT0 064.05TRUE00
2026-02-20350PUT0 069TRUE00

Latest ANAB Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST8$21.35
Jun 13, 2022 7:59 PM EST1$21.35
Jun 13, 2022 7:59 PM EST200$21.35
Jun 13, 2022 7:59 PM EST54$21.35
Jun 13, 2022 7:59 PM EST13$21.35

AnaptysBio, Inc (ANAB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm
2018-09-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1370053/000000000018028147/0000000000-18-028147-index.htm
2018-10-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1370053/000000000018032332/0000000000-18-032332-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000009375120000338/0000093751-20-000338-index.htm
2019-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000021545719003201/0000215457-19-003201-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000031506619000857/0000315066-19-000857-index.htm
2019-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000031506619001800/0000315066-19-001800-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000083423720004777/0000834237-20-004777-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000090266419000927/0000902664-19-000927-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000090266420000965/0000902664-20-000965-index.htm
2020-02-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000092189520000234/0000921895-20-000234-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000092963819000269/0000929638-19-000269-index.htm
2019-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093247119004736/0000932471-19-004736-index.htm
2019-11-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093583619000611/0000935836-19-000611-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093583620000141/0000935836-20-000141-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000436/0001012975-18-000436-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000437/0001012975-18-000437-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000438/0001012975-18-000438-index.htm
2018-05-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1370053/000107261318000346/0001072613-18-000346-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000110465920018330/0001104659-20-018330-index.htm
2018-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518089132/0001193125-18-089132-index.htm
2018-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518095907/0001193125-18-095907-index.htm
2018-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518280420/0001193125-18-280420-index.htm
2018-09-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1370053/000119312518281156/0001193125-18-281156-index.htm
2018-09-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1370053/000119312518283918/0001193125-18-283918-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518283933/0001193125-18-283933-index.htm
2019-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1370053/000119312519041203/0001193125-19-041203-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312520225721/0001193125-20-225721-index.htm
2018-03-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118017376/0001209191-18-017376-index.htm
2018-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118017377/0001209191-18-017377-index.htm
2018-04-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm
2018-07-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-08-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118045891/0001209191-18-045891-index.htm
2018-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118045892/0001209191-18-045892-index.htm
2018-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm
2018-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009006/0001209191-19-009006-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009024/0001209191-19-009024-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009028/0001209191-19-009028-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009031/0001209191-19-009031-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009034/0001209191-19-009034-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009036/0001209191-19-009036-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009038/0001209191-19-009038-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009043/0001209191-19-009043-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009044/0001209191-19-009044-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009046/0001209191-19-009046-index.htm
2019-04-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119046820/0001209191-19-046820-index.htm
2019-09-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119050888/0001209191-19-050888-index.htm
2019-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119050889/0001209191-19-050889-index.htm
2019-11-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm
2019-12-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm
2019-12-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119059923/0001209191-19-059923-index.htm
2019-12-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119059924/0001209191-19-059924-index.htm
2019-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119060981/0001209191-19-060981-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009309/0001209191-20-009309-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009316/0001209191-20-009316-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009322/0001209191-20-009322-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009325/0001209191-20-009325-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009327/0001209191-20-009327-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009329/0001209191-20-009329-index.htm
2020-03-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm
2020-07-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042503/0001209191-20-042503-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042505/0001209191-20-042505-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042506/0001209191-20-042506-index.htm
2020-07-313Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120044257/0001209191-20-044257-index.htm
2020-07-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120044259/0001209191-20-044259-index.htm
2019-11-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000121465919007372/0001214659-19-007372-index.htm
2018-06-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417318000087/0001274173-18-000087-index.htm
2019-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417319000033/0001274173-19-000033-index.htm
2019-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417319000125/0001274173-19-000125-index.htm
2019-08-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000131924419000074/0001319244-19-000074-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000131924420000020/0001319244-20-000020-index.htm
2018-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000020/0001370053-18-000020-index.htm
2018-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000022/0001370053-18-000022-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000026/0001370053-18-000026-index.htm
2018-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000027/0001370053-18-000027-index.htm
2018-05-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000029/0001370053-18-000029-index.htm
2018-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000031/0001370053-18-000031-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000036/0001370053-18-000036-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000037/0001370053-18-000037-index.htm
2018-09-1410-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000041/0001370053-18-000041-index.htm
2018-09-1410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000042/0001370053-18-000042-index.htm
2018-09-1410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000043/0001370053-18-000043-index.htm
2018-09-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000046/0001370053-18-000046-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000051/0001370053-18-000051-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000052/0001370053-18-000052-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000004/0001370053-19-000004-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000006/0001370053-19-000006-index.htm
2019-02-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000007/0001370053-19-000007-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000013/0001370053-19-000013-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000014/0001370053-19-000014-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000018/0001370053-19-000018-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000019/0001370053-19-000019-index.htm
2019-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000021/0001370053-19-000021-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000026/0001370053-19-000026-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000027/0001370053-19-000027-index.htm
2019-08-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000029/0001370053-19-000029-index.htm
2019-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000031/0001370053-19-000031-index.htm
2019-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000035/0001370053-19-000035-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000041/0001370053-19-000041-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000042/0001370053-19-000042-index.htm
2020-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000003/0001370053-20-000003-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000007/0001370053-20-000007-index.htm
2020-03-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000009/0001370053-20-000009-index.htm
2020-03-02S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000010/0001370053-20-000010-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000013/0001370053-20-000013-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000019/0001370053-20-000019-index.htm
2020-04-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000020/0001370053-20-000020-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000025/0001370053-20-000025-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000026/0001370053-20-000026-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000042/0001370053-20-000042-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000045/0001370053-20-000045-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000050/0001370053-20-000050-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000051/0001370053-20-000051-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000053/0001370053-20-000053-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000057/0001370053-20-000057-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000064/0001370053-20-000064-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000065/0001370053-20-000065-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000162363220000230/0001623632-20-000230-index.htm
2020-04-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000162363220000855/0001623632-20-000855-index.htm

AnaptysBio, Inc (ANAB) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of AnaptysBio, Inc (ANAB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 77%
Institutional Ownership: 10622%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-12-03Dominic PiscitelliChief Financial OfficerSell1,100.0075.8183,390.010.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell4,820.0072.24348,212.2210,022.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell6,624.0074.33492,361.921,100.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-09-07Marco LondeiChief Medical OfficerBuy142,857.000.7099,999.90144,877.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell6,741.0068.47461,577.84144,877.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell18,604.0071.331,327,060.5314,842.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell8,002.0067.57540,683.94151,618.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerBuy8,048.000.705,633.60152,925.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell3,185.0066.38211,416.16159,620.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell12,120.0065.36792,177.74162,805.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerBuy22,000.006.93152,460.00174,925.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2019-06-10Hamza SuriaPresident, CEOSell454.0076.3134,644.7417,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-10Hamza SuriaPresident, CEOSell1,994.0075.86151,270.8218,090.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-10Hamza SuriaPresident, CEOSell5,000.0074.68373,412.5020,084.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-01-15Marco LondeiChief Medical OfficerSell14,894.0070.041,043,195.1222,377.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell2,003.0074.50149,219.0922,377.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell2,048.0073.43150,383.8224,380.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-10Hamza SuriaPresident, CEOSell6,440.0073.70474,637.0225,084.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell6,009.0072.45435,358.6626,428.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2018-04-16Nicholas LydonDirectorSell2,222.0090.26200,549.05271,106.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-04-16Nicholas LydonDirectorSell2,803.0089.42250,631.37273,328.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-06-08Hamza SuriaPresident, CEOBuy22,428.002.5958,088.5227,426.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm
2018-04-16Nicholas LydonDirectorSell4,250.0088.30375,267.35276,131.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2019-11-22Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0027,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm
2018-04-16Nicholas LydonDirectorSell9,425.0087.46824,340.66280,381.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-07-09Hamza SuriaPresident, CEOBuy1,428.002.243,198.7228,854.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-04-16Nicholas LydonDirectorSell1,390.0086.15119,752.95289,806.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-04-16Nicholas LydonDirectorSell10,310.0085.11877,491.32291,196.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-12-11Hamza SuriaPresident, CEOSell4,998.0070.83354,008.3430,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-12Hamza SuriaPresident, CEOSell8,324.0072.88606,618.1630,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-14Hamza SuriaPresident, CEOSell7,800.0070.51549,978.7830,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2019-01-14Hamza SuriaPresident, CEOSell12,240.0071.10870,304.3930,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-04-16Nicholas LydonDirectorSell2,600.0084.18218,879.96301,506.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2019-06-10Hamza SuriaPresident, CEOSell8,540.0072.64620,384.8831,524.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-04Marco LondeiChief Medical OfficerBuy10,060.000.707,042.0032,437.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell3,554.0070.34249,974.1433,446.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-07-09Hamza SuriaPresident, CEOBuy6,208.001.619,994.8835,062.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-12-10Hamza SuriaPresident, CEOSell4,964.0072.48359,805.1235,062.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-12-10J. Anthony WareDirectorBuy3,600.0014.0550,580.003,600.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerBuy37,000.0011.34419,580.0037,000.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2019-01-15Marco LondeiChief Medical OfficerSell4,181.0069.29289,686.4437,271.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2020-02-05Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0037,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm
2018-12-14Hamza SuriaPresident, CEOSell9,084.0069.68632,967.6737,864.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-12Hamza SuriaPresident, CEOSell9,673.0071.92695,717.9538,388.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOSell10,347.0071.49739,700.8240,026.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-04-17Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0040,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm
2019-01-15Marco LondeiChief Medical OfficerBuy19,075.006.93132,189.7541,452.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-01-14Hamza SuriaPresident, CEOSell27,760.0070.651,961,227.3442,304.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-12-14Hamza SuriaPresident, CEOSell24,844.0068.891,711,428.6346,948.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2020-03-10Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0047,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm
2018-12-12Hamza SuriaPresident, CEOSell12,003.0071.11853,480.5248,061.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOSell15,276.0070.571,078,082.3150,373.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-12Hamza SuriaPresident, CEOBuy30,000.001.1233,600.0060,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOBuy30,587.001.1234,257.4465,649.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-11-27Marco LondeiChief Medical OfficerBuy46,202.006.93320,179.8668,579.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm
2019-01-14Hamza SuriaPresident, CEOBuy40,000.001.1244,800.0070,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-12-14Hamza SuriaPresident, CEOBuy41,728.001.1246,735.3671,792.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell2,298.0073.18168,158.687,724.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm